Document is current
Any future updates will be listed below
-
Authors
Zhang, Wenwen
Tong, Shuang
Hu, Bingyang
Wan, Tao
Tang, Haowen
Zhao, Feilong
Jiao, Tianyu
Li, Junfeng
Zhang, Ze https://orcid.org/0000-0003-1466-4767
Cai, Jinping
Ye, Huiyi
Wang, Zhanbo
Chen, Shiqing
Wang, Yafei
Li, Xuerui
Wang, Fangzhou
Cao, Junning
Tian, Lantian
Zhao, Xiaochen
Chen, Mingyi
Wang, Hongguang
Cai, Shouwang
Hu, Minggen
Bai, Yuezong
Lu, Shichun https://orcid.org/0009-0003-7444-734X
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03713593 at ClinicalTrials.govDocuments that mention this clinical trial
Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
https://doi.org/10.1200/jco.2024.42.3_suppl.482
Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial
https://doi.org/10.1136/jitc-2023-007366
34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1
https://doi.org/10.1186/s40425-019-0763-1
Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
https://doi.org/10.1200/jco.2023.41.4_suppl.506
- License Information
